Clinical Trials Logo

Clinical Marker clinical trials

View clinical trials related to Clinical Marker.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04582552 Recruiting - Ovarian Cancer Clinical Trials

The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer

ROMP
Start date: December 15, 2020
Phase:
Study type: Observational

Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy. PARP inhibitors(PARPi) are an important progress in EOC treatment. The available evidence suggests that BRCAmt or HRD-positive is an effective biological marker for PARPi. However, in our previous clinical observation, it was found that the tumor burden may be the potential clinical markers PARPi. We intend to develop a real-world study to confirm the potential clinical markers and explore new clinical markers for PARPi.